The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...

The U.S. Food and Drug Administration today approved Basaglar (insulin glargineinjection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 ...

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is ...

Eli Lilly and Boehringer Ingelheim announced today that their insulin glargine injection product, Basaglar® (a follow-on biologic for Sanofi’s Lantus®), is now available by prescription in the U.S. As ...

The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co's diabetes drug Basaglar, a cheaper version of Sanofi AG's top-selling drug Lantus. The drug, an injection known also as ...

Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced that Basaglar (insulin glargine injection 100 units/mL) is available by prescription in the US Basaglar is a follow-on ...

Eli Lilly and Boehringer Ingelheim launched Basaglar, a biosimilar referencing Sanofi’s blockbuster insulin drug Lantus, in South Korea on Thursday, intent on challenging the original drug’s dominance ...

Original Medicare (parts A and B) typically doesn’t cover Basaglar, an insulin glargine medication, but Medicare Advantage (Part C) and Part D plans may offer coverage depending on their specific ...

The FDA has granted tentative approval for Basaglar (insulin glargine injection), produced by Eli Lilly and Boehringer Ingelheim's (BI) diabetes alliance, following litigation filed by Sanofi claiming ...